Clinical trial
Gene Modified Allogeneic Neuroblastoma Cells For Treatment of…
NCT00186862 · St. Jude Children's Research Hospital, Other · Completed
Key facts
| NCT number | NCT00186862 |
|---|---|
| Title | Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma |
| Official title | Phase I Study of Chemokine and Cytokine Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma Using a Retroviral Vector |
| Lead sponsor | St. Jude Children's Research Hospital, Other |
| Collaborators | Texas Children's Cancer Center National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Drug |
| Interventions | Interleukin-2 |
| Enrollment | 24 |
| Start date | Aug 1, 1998 |
| Primary completion | Apr 1, 2000 |
| Completion | Oct 1, 2007 |
| First posted | Sep 16, 2005 |
| Last update posted | Jun 3, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: